GSK’s new PhI­II da­ta sup­port bid for wider en­dome­tri­al can­cer la­bel for Jem­per­li

GSK’s PD-1 an­ti­body Jem­per­li has hit the bench­mark in a late-stage en­dome­tri­al can­cer test, paving the way for a po­ten­tial la­bel ex­pan­sion be­yond its cur­rent …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER